D-0250-2021 Class III Terminated
FDA drug recall D-0250-2021 was initiated by Accord Healthcare, Inc. on Jan 28, 2021 and is designated Class III. Reason for recall: Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials The recall status is terminated (terminated Feb 8, 2022). Affected quantity: 502 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Feb 17, 2021
- Initiation Date
- Jan 28, 2021
- Termination Date
- Feb 8, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 502 cartons
Product description
Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA. Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)
Reason for recall
Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials
Distribution pattern
Nationwide
Code information
Lot: M2013645 Exp. Aug. 2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0250-2021
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026